VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
VNRX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
VNRXVolitionRx Limited
$1.40$7M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksVNRXBalance Sheet

VolitionRx Limited (VNRX) Balance Sheet

22Y historyFree accessUpdated daily

The company's financial position is increasingly vulnerable, with total debt rising to $11.5 million against a total asset base of only $6.9 million as of 2025Q4.

VNRX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Aug'10Aug'09Aug'08Aug'07Aug'06Aug'05Aug'04
Total Current Assets4.52M2.06M4.06M21.85M12.17M21.98M20.33M17.56M13.9M10.57M22.01M6.22M2.34M1.01M695.14K699.47K4853.44K3.32K4.34K2.26K10368
Cash & Short-Term Investments3.1M1.12M3.26M20.73M10.87M20.58M19.44M16.97M13.43M10.12M21.68M5.92M2.14M888.7K376.42K347.89K4853.44K3.32K4.34K2.26K10368
Cash Only3.1M1.12M3.26M20.73M10.87M20.58M19.44M16.97M13.43M10.12M21.68M5.92M2.14M888.7K376.42K347.89K4853.44K3.32K4.34K2.26K10368
Short-Term Investments00000000000000000000000
Accounts Receivable252.24K317.81K110.57K242.62K72.61K12.51K7.12K0000000000000000
Days Sales Outstanding39.5567.1532.72114.2286.550.72193.41----------------
Inventory00000598.37K00000000000000000
Days Inventory Outstanding-----------------------
Other Current Assets291.19K626.09K343.14K360.13K447.57K786.64K576.66K322.59K229.75K202.29K166.89K153.72K52.66K34.61K39.37K30.75K0000000
Total Non-Current Assets4.52M4.84M5.34M6.1M6.12M5.51M5.82M3.74M3.59M4.06M2.72M1.49M1.1M1.07M1.52M1.55M0000000
Property, Plant & Equipment4.2M4.52M5.03M6.07M6.01M5.29M5.5M3.36M3.12M3.48M2.12M783.8K288.58K63.27K91.39K22.97K0000000
Fixed Asset Turnover0.53x0.38x0.25x0.13x0.05x0.02x0.00x0.01x----0.05x-0.60x--------
Goodwill00000000000000000000000
Intangible Assets318.9K316.7K313.75K23.89K110.5K216.88K321.64K372.31K466.9K576.4K602.19K705.38K808.73K1M1.43M1.52M0000000
Long-Term Investments00000000000000000000000
Other Non-Current Assets00000000000000-1.52M00000000
Total Assets9.04M6.9M9.4M27.95M18.3M27.49M26.15M21.29M17.49M14.62M24.73M7.71M3.43M2.07M2.22M2.25M4853.44K3.32K4.34K2.26K10368
Asset Turnover0.32x0.25x0.13x0.03x0.02x0.00x0.00x0.00x----0.00x-0.02x--------
Asset Growth %-103.05%-26.58%-66.37%52.78%-33.45%5.12%22.82%21.74%19.59%-40.87%220.71%124.64%65.79%-6.59%-1.27%462838.97%-85.91%3.71%-23.51%92.2%2091.26%51.47%-
Total Current Liabilities13.85M12.23M7.79M8.94M17.39M6.52M6.24M3.86M2.33M2.29M2.03M1.12M2.71M957.27K747.77K534.36K114.77K110.98K99.24K82.66K58.48K73.04K64.1K
Accounts Payable3.72M2.92M2.77M3.21M3.04M1.54M1.54M627.25K807.16K351.74K281.18K323.51K797.91K518.09K481.39K255.52K97.72K95.63K99.24K82.66K58.48K73.04K64.1K
Days Payables Outstanding4.34K-------460.39236.66331.7--------7.54K---
Short-Term Debt4.26M3.31M860.22K1.21M1.07M797.86K841.32K647.57K561.7K582.99K149.67K81.34K0052.86K00000000
Deferred Revenue (Current)1.18M353.85K230K106.6K10M12.51K69.22K39.3K40.09K045.51K219.36K191.51K216.89K-481.39K00000000
Other Current Liabilities1.34M5.15M97.89K126.65K00-69.22K-39.3K-145.15K-139.08K-238.03K-162.68K1.58M222.29K0017.05K15.36K00000
Current Ratio0.33x0.17x0.52x2.44x0.70x3.37x3.26x4.55x5.96x4.61x10.82x5.56x0.86x1.05x0.93x1.31x0.00x0.03x0.03x0.05x0.04x0.00x0.00x
Quick Ratio0.33x0.17x0.52x2.44x0.70x3.28x3.26x4.55x5.96x4.61x10.82x5.56x0.86x1.05x0.93x1.31x0.00x0.03x0.03x0.05x0.04x0.00x0.00x
Cash Conversion Cycle-4.3K----------------------
Total Non-Current Liabilities28.55M30.26M27.72M27.72M4.04M3.25M3.62M3.23M3.02M2.38M1.52M547.87K351.77K432.81K635.2K621.93K0000000
Long-Term Debt6.35M7.26M3.95M3.62M2.78M2.27M2.61M2.2M2.7M1.31M432.03K000000000000
Capital Lease Obligations2.55M594.42K739.02K778.08K836.22K728.39K753.79K739.58K720.01K874.68K889.81K299.86K00000000000
Deferred Tax Liabilities00000000-311.04K-188.58K-202.32K-248.01K00000000000
Other Non-Current Liabilities464.93K473.65K361.24K422.71K420.47K253.22K00-408.97K00000000000000
Total Liabilities42.4M42.49M35.51M36.66M21.42M9.77M9.86M7.09M5.35M4.67M3.56M1.67M3.06M1.39M1.38M1.16M114.77K110.98K99.24K82.66K58.48K73.04K64.1K
Total Debt11.42M11.46M5.82M5.86M4.97M4.02M4.44M3.94M3.27M2.77M1.47M381.2K0052.86K00000000
Net Debt8.32M10.35M2.56M-14.87M-5.89M-16.56M-15M-13.03M-10.16M-7.35M-20.21M-5.53M-2.14M-888.7K-323.56K-347.89K-485-3.44K-3.32K-4.34K-2.26K-103-68
Debt / Equity-0.34x----0.23x0.27x0.28x0.27x0.28x0.07x0.06x--0.06x--------
Debt / EBITDA-0.56x----------------------
Net Debt / EBITDA-0.41x----------------------
Interest Coverage-7.07x-8.44x-79.09x-159.98x-175.78x-172.23x-156.16x-126.19x-161.35x-200.95x-------------
Total Equity-33.36M-35.59M-26.11M-8.71M-3.13M17.72M16.29M14.2M12.14M9.96M21.18M6.04M368.18K680.67K833.79K1.09M-114.29K-107.54K-95.92K-78.32K-56.23K-72.94K-64.03K
Equity Growth %-154.59%-36.33%-199.67%-178.62%-117.64%8.77%14.76%16.95%21.92%-52.97%250.33%1541.68%-45.91%-18.36%-23.43%1052.82%-6.27%-12.11%-22.48%-39.3%22.91%-13.91%-
Book Value per Share-4.85-6.66-6.03-2.45-1.136.737.207.257.747.5518.376.820.551.261.783.78-1.00-0.94-0.84-0.69-0.51-1.11-0.99
Total Shareholders' Equity-31.97M-34.25M-24.91M-7.8M-2.57M17.94M16.34M14.2M12.14M9.96M21.18M6.04M368.18K680.67K833.79K1.09M-114.29K-107.54K-95.92K-78.32K-56.23K-72.94K-64.03K
Common Stock7.93K125.78K96.1K81.9K57.87K53.77K48.61K41.13K35.34K26.52K26.13K18.76K14.69K11.68K10.19K8.65K2.29K2.29K2.29K2.29K2.29K1.29K1.29K
Retained Earnings-259.57M-252.9M-229.54M-202.58M-167.26M-136.99M-110.17M-89.82M-73.72M-55.71M-40.94M-29.04M-19.51M-11.3M-7.59M-3.5M-217.24K-206.29K-190.47K-168.67K-142.38K-105.39K-92.28K
Treasury Stock00000000000000000000000
Accumulated OCI-160.76K-295.07K385.63K243.94K227.1K148.33K-59.98K125.67K223.65K-129.34K-193.3K-84.17K-103.83K-59.8K-34.28K4.64K0000000
Minority Interest-1.39M-1.35M-1.2M-909.97K-551.97K-222.29K-47.18K0000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Severe liquidity and dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Capital Erosion Weakens Financial Position

As reported in recent financial statements, VNRX has seen its total assets contract from $28.0 million in 2023Q4 to $6.9 million by 2025Q4, reflecting a consistent depletion of resources as the company struggles to bridge the gap between research-heavy operations and commercial revenue generation.

The persistent decline in total assets, coupled with a deepening deficit in retained earnings, suggests that the company is consuming its capital base to fund ongoing clinical development. This trajectory indicates that the business model remains highly dependent on external financing to maintain its current operational footprint.

Leverage Rising Amidst Asset Contraction

Based on the company's reported figures, total debt has climbed from $5.9 million in 2023Q4 to $11.5 million in 2025Q4, creating a precarious leverage profile where debt obligations now significantly exceed the company's total asset base of $6.9 million.

The increase in debt during a period of asset contraction suggests that the company is utilizing credit facilities to sustain operations rather than for strategic growth initiatives. Investors should monitor this trend closely, as the inability to generate positive cash flow makes the current debt load appear increasingly unsustainable.

Critical Cash Runway Nears Exhaustion

According to the most recent quarterly filings, VNRX's cash position has plummeted to $1.1 million as of 2025Q4, resulting in a current ratio of 0.17 that highlights a severe lack of liquidity to cover near-term liabilities and ongoing research expenditures.

The rapid depletion of cash reserves from $20.7 million in 2023Q4 to current levels indicates that the company is operating with an extremely thin margin for error. This liquidity profile suggests that a dilutive capital raise or restructuring may be imminent to avoid a potential default on obligations.

Deferred Revenue Masks Operational Reality

As disclosed in the balance sheet, deferred revenue remains elevated at $22.3 million, which, when compared to the company's negative equity position of $34.2 million, suggests that a significant portion of the balance sheet is comprised of future performance obligations rather than tangible assets.

This high level of deferred revenue relative to total assets may indicate that the company has already recognized or utilized cash from future milestones, potentially limiting future revenue recognition. This distortion makes the headline balance sheet appear more stable than the underlying cash position would otherwise suggest.

VNRX — Frequently Asked Questions

Quick answers to the most common questions about buying VNRX stock.

What are the total assets of VolitionRx Limited (VNRX)?

As of 2025, VolitionRx Limited (VNRX) had total assets of $6.9M including $2.1M in current assets.

How much debt does VolitionRx Limited (VNRX) have?

VolitionRx Limited (VNRX) carries total debt of $11.5M, offset by $1.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of VolitionRx Limited?

VolitionRx Limited (VNRX) has total shareholders' equity (book value) of $-34.2M ($-6.66 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is VolitionRx Limited's current ratio and liquidity?

VolitionRx Limited (VNRX) reported a current ratio of 0.17x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.